Large-Scale NMN Trial Reports Meaningful NAD+ Elevation but Mixed Functional Outcomes
Large NMN trial shows 38% NAD+ increase but inconsistent functional benefits, questioning longevity supplement claims.
-
-
New Data Links TRT to Reduced All-Cause Mortality in Hypogonadal Men Over 65
New study shows testosterone therapy reduces death risk in older hypogonadal men, strengthening case for treatment.
-
AI-Designed Peptides Demonstrate Antimicrobial Activity Against Drug-Resistant Bacteria
AI-designed antimicrobial peptides show activity against drug-resistant bacteria including MRSA in laboratory testing.
-
Ultra-Short-Acting Neurotoxin BoNT/E Enters Phase 3 Trials With 24-Hour Onset Promise
AbbVie’s botulinum toxin type E candidate enters Phase 3 with the promise of cosmetic results within 24 hours versus 3-7 days for current Botox.
-
2026 Declared ‘Year of Regenerative Aesthetics’ as Industry Shifts From Fillers to Biologics
Aesthetic medicine pivots to biologic treatments and regenerative approaches, moving away from traditional fillers in 2026.
-
Exosome Therapy Receives FDA Orphan Drug Designation for Glioblastoma Treatment
FDA grants orphan drug status to exosome therapy targeting glioblastoma, offering hope for aggressive brain cancer treatment.
-
Exosome-Based Cosmeceuticals Emerge as Fastest-Growing Segment in Skincare Market
Exosome-based skincare products are the fastest-growing cosmeceutical segment, though experts urge caution on unproven claims.
-
FDA Reaffirms No Approved Exosome Therapies, Issues New Enforcement Actions Against Clinics
FDA confirms no exosome therapies are approved and takes enforcement action against clinics making unsubstantiated treatment claims.
-
Systematic Review Challenges NAD+ Supplementation Hype With Mixed Clinical Evidence
Lancet review finds NAD+ supplements raise cellular levels but lack consistent evidence for promised metabolic and anti-aging benefits.
-
PEARL Trial: Rapamycin Shows Significant Anti-Aging Benefits in First Large Human RCT
PEARL trial shows rapamycin reduces biological age by 2.1 years in first large randomized study of anti-aging intervention.
